ArticleBMC cancer2025
NRF2 expression level and estrogen function in BRCA1-mutated breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most common malignancy diagnosed in women, with approximately 5–10% of cases attributed to hereditary factors. Although the tumor suppressor breast cancer susceptibility gene 1(BRCA1) is ubiquitously expressed, it is not clear why BRCA1 mutations overwhelmingly predispose to breast and ovarian cancers. Estrogen has been proposed to promote the survival of BRCA1-deficient cells under oxidative stress by activating nuclear factor erythroid-2-related factor 2 (NRF2), potentially driving malignant transformation. This study investigates the role of estrogen and NRF2 expression in BRCA1-mutated breast cancer.
methodsWe analyzed 70 formalin-fixed, paraffin-embedded (FFPE) tissue samples (tumor and adjacent non-tumoral) from 15 BRCA1-mutated breast cancer patients and 20 non-mutated controls. Both adjacent non-tumoral and tumoral breast tissue were paired samples from the same patient for the two groups. NRF2 expression was quantified using qRT-PCR, while estrogen activity was indirectly assessed via immunohistochemical (IHC) analysis of focal adhesion kinase (FAK) protein expression.
resultsNRF2 was significantly overexpressed in BRCA1-mutated tumors compared to controls (p = 0.036). In contrast, no significant difference in estrogen-mediated FAK expression was observed between BRCA1-mutated and control tumors.
conclusionsOur findings indicate that NRF2 upregulation is a distinguishing feature of BRCA1-mutated breast cancer, suggesting its potential involvement in tumorigenesis. These results offer new paths into targeted prevention and therapeutic strategies for BRCA1-mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.